Summary

Eligibility
for people ages 18-65 (full criteria)
Location
at UCSF
Dates
study started
completion around

Description

Summary

The purpose of this study is to evaluate the efficacy and safety of JNJ-78934804 as compared to guselkumab and golimumab in participants with moderately to severely active ulcerative colitis who have had an inadequate initial response, loss of response, or intolerance to one or more approved advanced therapy.

Official Title

A Phase 2b Randomized, Double-blind, Active-and Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Efficacy and Safety of Induction and Maintenance Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Ulcerative Colitis

Keywords

Colitis, Ulcerative, Colitis, Ulcerative Colitis, Ulcer, Golimumab, Guselkumab, JNJ-78934804

Eligibility

Locations

  • University of California San Francisco
    San Francisco California 94115 United States
  • Cedars Sinai Medical Center
    Los Angeles California 90048 United States
  • Southern California Research Center
    Coronado California 92118 United States
  • Valley Gastroenterology Medical Group
    Arcadia California 91006 United States

Details

Status
in progress, not accepting new patients
Start Date
Completion Date
(estimated)
Sponsor
Janssen Research & Development, LLC
ID
NCT05242484
Phase
Phase 2 research study
Study Type
Interventional
Participants
About 577 people participating
Last Updated